目的 讨论替吉奥联合奥沙利铂治疗晚期胃癌患者的临床疗效。方法 选取2016年3—2017年3月青海大学附属医院收治的晚期胃癌患者80例，随机分为对照组和治疗组，每组各40例。对照组静脉滴注注射用奥沙利铂，90 mg/m²溶于5%葡萄糖溶液500 mL，持续3～4 h，1次/14 d。治疗组在对照组的基础上口服替吉奥胶囊，2粒/次，2次/d。两组患者持续治疗28 d。观察两组患者临床疗效，比较治疗前后两组患者生存质量及血清肿瘤坏死因子-α（TNF-α）、白介素-6（IL-6）和IL-10水平。结果 治疗后，对照组客观缓解率和疾病控制率分别为52.5%、72.5%，均分别显著低于治疗组的77.5%、92.5%，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组躯体功能、情绪功能、认知功能和社会功能评分显著高于对照组，食欲下降、便秘和睡眠障碍症状评分显著低于对照组，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后两组上述评分均显著优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者血清TNF-α、IL-6、IL-10水平均显著低于治疗前，同组比较差异具有统计学意义（P<0.05）；且治疗组患者上述血清因子水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 替吉奥联合奥沙利铂治疗晚期胃癌临床疗效较好，能改善患者的生存质量，有效降低患者血清TNF-α、IL-6、IL-10的表达，具有一定的临床应用价值。

Objective To discuss the curative effect of tegafur, gimeracil and oteracil potassium combined with oxaliplatin in treatment of advanced gastric cancer. Methods Patients (80 cases) with advanced gastric cancer in Affiliated Hospital of Qinghai University from March 2016 to March 2017 were randomly divided into control and treatment groups, and each group had 40 cases. Patients in the control group were iv administered with Oxaliplatin for injection, 90 mg/m² added into 5% glucose solution 500 mL, and maintained for 3-4 h, once every 14 d. Patients in the treatment group were po administered with Tegafur, Gimeracil and Oteracil Potassium Capsules on the basis of the control group, 2 grains/time, twice daily. Patients in two groups were treated for 28 d. After treatment, the clinical efficacy was evaluated, and the quality of life, serum TNF-α, IL-6, and IL-10 levels in two groups before and after treatment were compared. Results After treatment, the ORR and CBR in the control group were 52.5% and 72.5%, which were significantly lower than 77.5% and 92.5% in the treatment group, respectively, and there were differences between two groups (P < 0.05). After treatment, physical function, emotional function, cognitive function, and social function scores in two groups were significantly increased, and the symptom of loss of appetite, constipation, and somnipathy scores significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And those scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the TNF-α, IL-6 and IL-10 levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these serum factors levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Tegafur, gimeracil and oteracil potassium combined with oxaliplatin can effectively reduce serum TNF-α, IL-6 and IL-10 levels and improve quality of life in treatment of advanced gastric cancer.